Kumar Neil 的 Form 4 申報
BridgeBio Pharma, Inc.（BBIO），2026/5/11 申報
- 申報編號
- 0001470831-26-000423
- 申報時間
- 2026/5/11
- 交易日
- 2026/5/7-5/8
- 申報延遲
- 4 天
- 10b5-1 計畫
- 有勾選
這份申報列了 12 筆非衍生性交易。公開市場賣出合計 $539.2 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kumar NeilCIK 0001742485 | 董事、高階主管（執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/5/7 | Common Stock | S賣出處分 | −11,217 | $67.50F2 | −$757,147.5 | 584,469 | 間接 | |
| 2026/5/7 | Common Stock | S賣出處分 | −8,333 | $68.38F4 | −$569,810.54 | 576,136 | 間接 | |
| 2026/5/7 | Common Stock | S賣出處分 | −450 | $69.09F5 | −$31,090.5 | 575,686 | 間接 | |
| 2026/5/7 | Common Stock | S賣出處分 | −11,217 | $67.49F2 | −$757,035.33 | 4,387,230 | 間接 | |
| 2026/5/7 | Common Stock | S賣出處分 | −8,334 | $68.38F4 | −$569,878.92 | 4,378,896 | 間接 | |
| 2026/5/7 | Common Stock | S賣出處分 | −449 | $69.09F5 | −$31,021.41 | 4,378,447 | 間接 | |
| 2026/5/8 | Common Stock | S賣出處分 | −13,973 | $66.65F6 | −$931,300.45 | 561,713 | 間接 | |
| 2026/5/8 | Common Stock | S賣出處分 | −5,077 | $67.35F7 | −$341,935.95 | 556,636 | 間接 | |
| 2026/5/8 | Common Stock | S賣出處分 | −950 | $68.35F8 | −$64,932.5 | 555,686 | 間接 | |
| 2026/5/8 | Common Stock | S賣出處分 | −13,974 | $66.65F6 | −$931,367.1 | 4,364,473 | 間接 | |
| 2026/5/8 | Common Stock | S賣出處分 | −5,076 | $67.35F7 | −$341,868.6 | 4,359,397 | 間接 | |
| 2026/5/8 | Common Stock | S賣出處分 | −950 | $68.35F8 | −$64,932.5 | 4,358,447 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F4
Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F5
Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F6
Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F7
Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F8
Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。